Skip to main content
Clinical Trials/NCT05691972
NCT05691972
Completed
Not Applicable

A Randomized, No-treatment-controlled, Evaluator-blinded, Multi-center Study to Evaluate the Effectiveness and Safety of Restylane Contour in the Treatment of Temple Hollowing

Galderma R&D1 site in 1 country225 target enrollmentMarch 14, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Temporal Hollowing
Sponsor
Galderma R&D
Enrollment
225
Locations
1
Primary Endpoint
Responder rate based on the Blinded Evaluators' live assessment of the GTVDS
Status
Completed
Last Updated
last year

Overview

Brief Summary

This is a randomized, no-treatment-controlled, evaluator-blinded, multi-center study to evaluate the effectiveness and safety of Restylane® Contour in correction of temple hollowing.

Registry
clinicaltrials.gov
Start Date
March 14, 2023
End Date
December 11, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Males or non-pregnant, non-breastfeeding females, 22 years of age or older
  • Intent to undergo treatment for correction of temple hollowing

Exclusion Criteria

  • Known/previous allergy or hypersensitivity to any injectable hyaluronic acid (HA) gel or to gram positive bacterial proteins
  • Known/previous allergy or hypersensitivity to local anesthetics, e.g., lidocaine or other amide-type anesthetics or nerve blocking agents (if intended to be used for that subject)
  • Previous facial surgery (e.g., facelift) above the level of the horizontal line from subnasale that in the Treating Investigator´s opinion could interfere with the study safety and/or effectiveness assessments
  • Any previous aesthetic procedures or implants
  • Recurrent temporal headaches such as temporal tendinitis migraine. Have a history of migraines or frequent headaches, as determined by the (Treating) Investigator, that could interfere with the study safety and/or effectiveness assessments

Outcomes

Primary Outcomes

Responder rate based on the Blinded Evaluators' live assessment of the GTVDS

Time Frame: Baseline to 3 months

Secondary Outcomes

  • Responder rates, as assessed by the Blinded Evaluator at 6, 9 and 12 months after baseline for the treatment group(6,9,12 months after baseline)

Study Sites (1)

Loading locations...

Similar Trials